In silico screening of drug databases for TSE inhibitors

BioSystems

Volumn 80, Issue 2, 2005, Pages 117-122

  Lorenzen, Stephan ^a   Dunkel, Mathias ^a   Preissner, Robert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

2D; 3D; Drug database; Inhibitor; Prion; Scrapie

Indexed keywords

AMODIAQUINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ASTEMIZOLE; BUDESONIDE; CHLOROQUINE; CLOMIFENE; CLOPENTHIXOL; ETHACRIDINE; HYDROXYCHLOROQUINE; MEPACRINE; METOPIMAZINE; MEVINOLIN; MIZOLASTINE; NEUROLEPTIC AGENT; OPIPRAMOL; OXOMEMAZINE; PERAZINE; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; RUPATADINE; THIORIDAZINE; TIOTIXENE; TOREMITENE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG DEVELOPMENT;

ARTICLE; COMPUTER MODEL; DATA BASE; DRUG EFFECT; DRUG IDENTIFICATION; DRUG SCREENING; METHODOLOGY; PRION DISEASE;

EID: 17044429758     PISSN: 03032647     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biosystems.2004.10.004     Document Type: Article

References (13)

1. A. Barret, F. Tagliavini, G. Forloni, C. Bate, M. Salmona, L. Colombo, A. De Luigi, L. Limido, S. Suardi, G. Rossi, F. Auvre, K.T. Adjou, N. Sales, A. Williams, C. Lasmezas, and J.P. Deslys Evaluation of quinacrine treatment for prion diseases J. Virol. 77 2003 8462 8469
2. M.P. Bradley An overview of the diversity represented in commercially available databases Mol. Divers. 5 2002 175 183
3. J.S. Delaney Assessing the ability of chemical similarity measures to discriminate between active and inactive compounds Mol. Divers. 1 1996 217 222
4. Goede, A., Dunkel, M., Mester, N., Frommel, C., Preissner, R., 2005. SuperDrug: a conformational drug database. Bioinformatics. PMID: 15691861, in press.
5. D.A. Kocisko, G.S. Baron, R. Rubenstein, J. Chen, S. Kuizon, and B. Caughey New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products J. Virol. 77 2003 10288 10294
6. C. Korth, B.C. May, F.E. Cohen, and S.B. Prusiner Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease Proc. Natl. Acad. Sci. U.S.A. 98 2001 9836 9841
7. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26
8. Y.C. Martin, J.L. Kofron, and L.M. Traphagen Do structurally similar molecules have similar biological activity J. Med. Chem. 45 2002 4350 4358
9. M. Nakajima, T. Yamada, T. Kusuhara, H. Furukawa, M. Takahashi, A. Yamauchi, and Y. Kataoka Results of quinacrine administration to patients with Creutzfeldt-Jakob disease Dement Geriatr. Cogn. Disord. 17 2004 158 163
10. M. Thimm, A. Goede, S. Hougardy, and R. Preißner Comparison of 2D similarity and 3D superposition. Application to searching a conformational drug database J. Chem. Inf. Comput. Sci. 44 2005 1816 1822
11. J.H. Voigt, B. Bienfait, S. Wang, and M.C. Nicklaus Comparison of the NCI open database with seven large chemical structural databases J. Chem. Inf. Comput. Sci. 41 2001 702 712
12. C.G. Wermuth Selective optimization of side activities: another way for drug discovery J. Med. Chem. 47 2004 1303 1314
13. WHO, 2003. The Selection and Use of Essential Medicines. Report of the WHO Expert Committee, 2002 (including the 12th Model list of essential medicines). World Health Organ Tech. Rep. Ser. 914 (i-vi), 1-126.